PLX stock forecast
Our latest prediction for Protalix Biotherapeutics, Inc.'s stock price was made on the May 16, 2017 when the stock price was at 0.83$.
In the short term (2weeks), PLX's stock price should outperform the market by 5.54%. During that period the price should oscillate between -6.58% and +18.39%.
In the medium term (3months), PLX's stock price should outperform the market by 11.86%. During that period the price should oscillate between -14.10% and +51.89%.Get email alerts
About Protalix Biotherapeutics, Inc.
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
At the moment the company generates 10M USD in revenues.
On its last earning announcement, the company reported a loss of -0.35$ per share.
The book value per share is None$
Three months stock forecastMay 16, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|